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Increasing evidence indicates that endoplasmic reticulum stress (ER stress) is involved
in the development of metabolic syndrome. However, pharmacological treatments target-
ing ER stress are not well understood. In the present study, we found that ﬂuvoxamine, a
selective serotonin reuptake inhibitor used for depression, can attenuate ER stress-induced
“leptin resistance,” i.e., insensitivity to the anti-obesity hormone leptin.Treatmentwith tuni-
camycin, an ER stress-inducing reagent, caused cell death which was signiﬁcantly inhibited
by ﬂuvoxamine. Leptin activates JAK2–STAT3 signaling. ER stress caused an impairment
of leptin-induced STAT3 phosphorylation which was reversed by ﬂuvoxamine. Fluvoxamine
would be a novel leptin-sensitizing drug, which targets ER stress.
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INTRODUCTION
Obesity is associated with Type 2 diabetes, cardiovascular disease,
and hypertension. However, the molecular mechanisms and phar-
macological treatment of obesity are notwell understood. Leptin is
an anti-obesity hormone, identiﬁed in 1994 (Zhang et al., 1994).
As it has an inhibitory effect on appetite, and stimulatory effect
on energy metabolism, leptin was initially expected to be use-
ful for treating obesity. However, recent evidence suggests that
most obese patients are in a state of “leptin resistance,” and can-
not adequately respond to circulating levels of leptin (Münzberg
and Myers, 2005). These observations have led to the notion that
“leptin resistance” is a major cause of obesity and elucidating the
mechanisms responsible would be useful for treating obesity. We
and others have recently proposed endoplasmic reticulum stress
(ER stress) to be involved in the development of leptin resistance
(Hosoi et al., 2008; Zhang et al., 2008; Hosoi and Ozawa, 2009,
2010; Milanski et al., 2009; Özcan et al., 2009; Won et al., 2009).
The ER is involved in maintaining Ca2+ homeostasis, synthesiz-
ing lipids and steroids, and correcting the folding of newly made
proteins. However, stress signals, which impair ER function, can
lead to the accumulation of unfolded proteins, resulting in ER
stress. In recent years, the involvement of ER stress in metabolic
syndrome has been suggested. However, compounds targeting ER
stress are an enigma. One interesting report found that the sigma-
1 receptor (Sig-1R) can counteract the ER stress response, and that
decreasing receptor numbers enhances apoptosis (Hayashi and Su,
2007). Sig-1R is an ER protein, ﬁrst cloned in 1996 (Hanner et al.,
1996). Sig-1R has been shown to play an important role in bio-
logical as well as pathological processes in the brain of patients
with Alzheimer’s disease, depression, and stroke (Maurice and Su,
2009; Fishback et al., 2010). Interestingly, ﬂuvoxamine, a selective
serotonin reuptake inhibitor used to treat depression, has afﬁnity
forSig-1R (Narita et al., 1996). Moreover, ﬂuvoxamine potentiated
nerve growth factor-induced neurite outgrowth through Sig-1R
(Takebayashi et al., 2002; Nishimura et al., 2008). These results
suggest that ﬂuvoxamine can reduce ER stress through Sig-1R.
We hypothesized that ﬂuvoxamine can reduce ER stress and the
subsequent development of “leptin resistance.”
MATERIALS AND METHODS
MATERIALS AND REAGENTS
Tunicamycin was obtained from Wako Pure Chemical Industries,
Ltd. (Japan). Leptin and ﬂuvoxamine were obtained from SIGMA
(St. Louis, MO, USA).
CELL CULTURE
Human neuroblastoma SH-SY5Y cells were maintained in Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% (v/v)
heat-inactivated fetal calf serum at 37˚C in humidiﬁed 5% CO2
and 95% air.
GENERATION OF OB–RB LEPTIN RECEPTOR-TRANSFECTED CELLS
The human Ob–Rb leptin receptor construct, a gift from Genen-
tech Inc., was transfected into SH-SY5Y and HEK293 cell using
Lipofectamine Plus reagent (Life Technologies Inc.) according to
the manufacturer’s instructions. Stable transfectants (SH-SY5Y–
Ob–Rb and HEK293–Ob–Rb cells) were obtained by selection
with the antibiotic G418 (Hosoi et al., 2006).
WESTERN BLOT ANALYSIS
Western blotting was performed as described previously (Hosoi
et al., 2010a,b). Cells were washed with ice-cold PBS and lysed
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in a buffer containing 10 mM HEPES–NaOH (pH 7.5), 150 mM
NaCl, 1 mM EGTA, 1 mM Na3VO4, 10 mM NaF, 10μg/mL apro-
tinin, 10μg/mL leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF), and 1% NP-40 for 20 min. The lysate was centrifuged
at 15,000 rpm for 20 min at 4˚C, and the supernatant was col-
lected. The samples were boiled with laemmli buffer for 3 min,
fractionated by sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE), and transferred at 4˚C to nitrocellulose
membranes. The membranes were incubated with anti-phospho
STAT3 (Tyr705: Cell Signaling; 1:1,000), anti-STAT3 (Santa
Cruz; 1:1,000), anti-KDEL (StressGen; 1:1,000), and anti-PARP
(Santa Cruz; diluted to 1:1,000) antibodies followed by an anti-
horseradish peroxidase-linked antibody. Peroxidase was detected
by chemiluminescence using an enhanced chemiluminescence
system.
RNAi EXPERIMENT
Transient transfections of siRNA were performed in HEK293-
Ob–Rb cells. Lipofectamine RNAiMAX (Life technologies) was
used to transfect siRNA according to the manufacturer’s direc-
tions. Opti-MEM1 medium was used for the transfection and the
ﬁnal concentrations of siRNA were 50 nM. We knocked down
Sig-1R using the following siRNA sequence: human Sig-1R; 5′-
CUC ACU AAC UGA GGC CUU UdTdT-3′. We used MISSION
siRNA Universal Negative Control (SIGMA; SIC-001) for the
control siRNA transfection. Cells were harvested 72 h after the
transfection.
LACTATE DEHYDROGENASE LEAKAGE ASSAY
The viability of cells was estimated by the lactate dehydroge-
nase (LDH) leakage method using a cytotoxicity detection kit
(Roche Molecular Biochemicals, Indianapolis, IN, USA) accord-
ing to the manufacturer’s directions. LDH activity was measured
as the optimal density at 492 nm.
ANIMALS
ob/ob Mice were obtained from Japan SLC (Hamamatsu, Japan).
Mice were maintained in a room at 22–24˚C under a con-
stant day-night rhythm and given food and water, ad libitum.
All animal experiments were carried out in accordance with
the NIH Guide for Care and Use of Laboratory Animals and
approved by the animal care and use committee at Hiroshima
University.
MEASURING FOOD INTAKE
Nineweeks old female ob/obmicewere housed individually before
this experiment. Three days after the isolation, saline (5 ml/kg) as
a dummy was injected intraperitoneally (i.p.) for 3 days, and then
we injected leptin (1 mg/kg, i.p.) and/or ﬂuvoxamine (20 mg/kg).
All treatments were started at 18:00. Measuring cumulative food
intake was performed by measuring the weight of food at the
speciﬁc time points.
STATISTICS
Results are expressed as the mean± SE. The statistical analysis was
performed using Student’s t -test.
RESULTS
FLUVOXAMINE ATTENUATED ENDOPLASMIC RETICULUM
STRESS-INDUCED CELL DEATH
As ﬂuvoxamine has afﬁnity for Sig-1R (Narita et al., 1996), and Sig-
1R is involved in ER stress (Hayashi and Su, 2007), we analyzed
whether ﬂuvoxamine could attenuate ER stress. Tunicamycin (Tm)
was used to speciﬁcally induce ER stress. As shown in Figure 1, we
observed an increase in GRP78 in tunicamycin-treated cells, indi-
cating ER stress. In addition, tunicamycin treatment caused PARP
cleavage (Figure 1) and cell death as assessed by the LDH leak-
age assay (Figure 2). The results suggest that tunicamycin induces
FIGURE 1 | Specific inducer of ER stress, tunicamycin, evoked GRP78
expression, and PARP cleavage. SH-SY5Y cells were stimulated with
tunicamycin (Tm: 0.5μg/mL) for 24 h. Levels of GRP78 expression and
PARP cleavage were analyzed byWestern blotting.
FIGURE 2 | Fluvoxamine attenuated ER stress-induced cell death.
SH-SY5Y cells were pre-incubated with ﬂuvoxamine (FVX: 0.1μM, 0.3μM)
for 1 h and then stimulated with tunicamycin (Tm: 0.5μg/mL) for 36 h. LDH
activity was measured as an indicator of cytotoxicity. *P <0.05.
Frontiers in Endocrinology | Cellular Endocrinology January 2012 | Volume 3 | Article 12 | 2
Hosoi et al. Fluvoxamine attenuated leptin resistance
ER stress-evoked apoptosis in human neuroblastoma SH-SY5Y
cells. To evaluate the pharmacological properties of ﬂuvoxam-
ine, we next analyzed its effect on ER stress-induced cell death.
Cells were pre-treated with ﬂuvoxamine for 30 min and ER stress
(tunicamycin)-induced cell death was analyzed. Treatment with
ﬂuvoxamine alone did not affect cell death (Figure 2). How-
ever, ﬂuvoxamine dose-dependently attenuated ER stress-induced
cell death (Figure 2). These results suggest that ﬂuvoxamine can
attenuate ER stress.
FLUVOXAMINE ATTENUATED ENDOPLASMIC RETICULUM
STRESS-INDUCED LEPTIN RESISTANCE
We and others had recently reported the involvement of ER
stress in leptin resistance (Hosoi et al., 2008; Zhang et al., 2008;
Milanski et al., 2009; Özcan et al., 2009; Won et al., 2009). As
ﬂuvoxamine attenuated ER stress, we next examined whether it
can reduce ER stress-induced leptin resistance. Consistent with a
previous report (Hosoi et al., 2008), leptin-induced STAT3 phos-
phorylation was inhibited in ER stressed SH-SY5Y cells stably
transfected with the Ob–Rb leptin receptor (Figure 3). Thus, we
next analyzed whether ﬂuvoxamine could reverse the ER stress-
induced impairment of leptin’s signaling. As shown in Figure 3,
we observed a dose-dependent recovery of STAT3 phosphory-
lation in ﬂuvoxamine-treated cells. Furthermore, we found that
FIGURE 3 | Fluvoxamine restored ER stress-induced leptin resistance.
(A) SH-SY5Y–Ob–Rb cells were pre-treated with ﬂuvoxamine (FVX: 0.1μM)
for 1 h and then treated with tunicamycin (Tm: 0.5μg/mL). Four hours after
the tunicamycin treatment, the cells were stimulated with leptin (Lep:
0.5μg/mL) for 15min and the phosphorylation status of STAT3 was
analyzed.Western blotting was performed using speciﬁc antibodies for
phospho STAT3 and STAT3. (B) Densitometric analysis of STAT3
phosphorylation using image analyzing software.
knocking down endogenous Sig-1R by siRNA reduced leptin-
induced STAT3 phosphorylation (Figure 4). The results suggest
that Sig-1R might be involved in downstream signal of lep-
tin’s action. Overall, these results suggest that ﬂuvoxamine could
attenuate leptin resistance.
To further evaluate the effect of ﬂuvoxamine on anti-obesity
property of leptin’s action, we next investigated in vivo function
of this drug. In the present study, we used ob/ob mice to evaluate
the pharmacological action. The mouse is used for obesity model,
which has no functional leptin due to the mutation of ob gene.
Moreover, the mouse has been shown to cause ER stress (Özcan
et al., 2004). Therefore, we investigated whether ﬂuvoxamine can
enhance leptin’s action by measuring food intake. Treatment with
leptin (1 mg/kg/day) reduced food intake. On the other hand,
treatment with ﬂuvoxamine alone slightly increased food intake
(Saline vs. ﬂuvoxamine: 30.3± 1.7 vs. 37.5± 2.8 g, cumulative
food intake of 6 days, respectively). However, efﬁciency of leptin’s
action in inhibiting food intake was signiﬁcantly decreased in ﬂu-
voxamine+ leptin-treated mice compared with leptin-treatment
alone (Figure 5). Therefore, these results suggest that ﬂuvoxamine
can improve leptin’s action in ob/ob mice model.
DISCUSSION
In recent years, obesity has become a serious health concern in
industrialized countries. It is thus important to evaluate the mech-
anisms and pharmacological treatment of obesity, although effec-
tive treatments have yet to be established. In the present study, we
discovered a pharmacological strategy targeting“leptin resistance,”
a major cause of obesity. We found that ﬂuvoxamine attenuated
leptin resistance caused by ER stress. Using ob/ob mice as obesity
model, we found that ﬂuvoxamine can slightly increase respon-
siveness of leptin’s action. Although the pharmacological property
of ﬂuvoxamine would be weak, our ﬁnding would point another
novel type of anti-obesity drugs,which would be a lead compound
for the more efﬁcient treatments.
Fluvoxamine would affect leptin resistance by attenuating ER
stress, because it inhibited ER stress-induced cell death. Fluvoxam-
ine is a selective serotonin (5-HT: 5-hydroxtryptamine) reuptake
inhibitor (SSRI) used for depression.The involvement of serotonin
in the inhibition of obesity has been suggested in studies using sev-
eral agentswhich activate the brain’s serotonin system (Guy-Grand
et al., 1989; Jackson et al., 1997; Lucas et al., 1998). Fluvoxamine
attenuated food intake in food-restricted hyperphagic rats (Shi-
nozaki et al., 2008) and during rebound hyperphagia induced
by a time-restricted feeding schedule in rats (Inoue et al., 1997).
These pharmacological effects of ﬂuvoxamine would be mediated
through the serotonin system. However, in addition to its phar-
macological effect as a SSRI, ﬂuvoxamine possesses high afﬁnity
for Sig-1R, an ER protein involved in ER stress (Hayashi and Su,
2007). We found that ﬂuvoxamine can attenuate ER stress. Thus,
ﬂuvoxamine would have a novel pharmacological action, targeting
ER stress-induced leptin resistance. At present, the mechanisms
how ﬂuvoxamine attenuated ER stress and leptin resistance are
enigma but our results suggest it would be mediated through
Sig-1R because knocking down Sig-R1 reduced leptin-induced
signal. Interestingly, Sig-R1 is expressed in several hypothalamic
areas involved in food intake such as paraventricular and arcuate
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FIGURE 4 | Knocking down sigma-1 receptor attenuated leptin’s
signal. (A)Western blot analysis of endogenous sigma-1 receptor
(Sig-1R) expression in lysates of HEK293-Ob–Rb cells transfected with
siRNA (50 nM) directed at Sig-1R or the control sequence. Sig-1R
siRNA reduced the expression of Sig-1R compared with control siRNA.
(B) Sig-1R siRNA decreased leptin-induced STAT3 phosphorylation
compared with control siRNA. HEK293-Ob–Rb cells were transfected
with 50 nM siRNA and treated with leptin (0.5μg/mL) for 15min.
Western blot analysis was then performed. *P <0.05 compared with
control siRNA.
FIGURE 5 | Effect of fluvoxamine on leptin-induced food intake. ob/ob
Mice were treated with ﬂuvoxamine (Fvx) along with leptin and analyzed
food intake. The effect of leptin on food intake were presented as
percentage of saline vs. leptin or ﬂuvoxamine vs. ﬂuvoxamine+ leptin.
Fluvoxamine signiﬁcantly enhanced the efﬁciency of the leptin’s action on
inhibiting food intake. *P <0.05 compared with leptin-treatment.
nuclei (Alonso et al., 2000). Therefore, it is of interest to exam-
ine whether there exist a physiological link between Sig-R1 and
leptin’s action. It is unknown whether physiological function of
hypothalamic Sig-R1 is impaired in obesity, which would need
future analysis.
Interestingly, clinical studies indicate a possible association
between obesity and depression (Faith et al., 2002; Stunkard et al.,
2003). It has been reported that obese patients are more likely to
have depressive disorders than non-obese people (Simon et al.,
2006). Considering the link between leptin and depression, and
that leptin has an anti-depressive effect in mice models (Lu et al.,
2006; Lu, 2007), it is possible that depression is linked with lep-
tin resistance, and the pharmacological effects of ﬂuvoxamine in
attenuating leptin resistance would contribute to the therapeutic
action against depression.
CONCLUSION
Our observation suggest that ﬂuvoxamine has unique pharmaco-
logical properties in attenuating leptin resistance. It is of interest
to investigate whether ﬂuvoxamine can also attenuate leptin resis-
tance evoked by physiological stimuli-induced leptin resistance.
Clearly, further studies are required to determine whether the ﬂu-
voxamine has leptin-sensitizing effect in human levels to conclude
our hypothesis.
Our present study suggest that ﬂuvoxamine would contribute
to attenuate pathophysiology of leptin resistance, which may pro-
vide basic information for treating obesity as well as depressive
disorders.
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